Cardiol Therapeutics (CRDL)

$2.17 0.19 (8.05%)

16:00 EDT CRDL Stock Quote Delayed 30 Minutes

CRDL Stock Earnings: Cardiol Therapeutics Meets EPS for Q1 2024

By InvestorPlace Earnings May 14, 2024

CRDL stock results show that Cardiol Therapeutics met analyst estimates for earnings per share the first quarter of 2024.

CRDL Stock Earnings: Cardiol Therapeutics Beats EPS for Q4 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

More Articles

Volume:

Previous Close -

Market Cap -

PE Ratio -

EPS -

Volume (Avg. Vol.) 345,211

Day's Range $2.13 - $2.40

52-Week Range $0.66 - $2.41

Dividend & Yield N/A (N/A)

CRDL Stock Predictions, Articles, and Cardiol Therapeutics News

From InvestorPlace
From the Web

CRDL Stock: 7 Things to Know About Healthcare Play Cardiol Therapeutics

By Chris MacDonald, InvestorPlace Contributor Oct 26, 2021

Today, CRDL stock is down despite very positive news of a Health Canada approval for a Phase 2 trial of the company's leading drug.

Short Squeeze Stocks: VRPX, CRDL and 3 Others Experts Think Are Ready to Pop

By Nick Clarkson, Web Editor Aug 23, 2021

As we begin another week, here's a look at some of the best short squeeze stocks available to investors according to research from Fintel.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

By William White, InvestorPlace Writer Aug 17, 2021

Good morning! We're starting off another busy day of trading with a dive into the biggest pre-market stock movers for Tuesday.

Cardiol stock rallies 28% on FDA orphan drug status for CardiolRx (NASDAQ:CRDL)

From Seeking Alpha Feb 15, 2024

Cardiol Therapeutics' (CRDL) stock surged 28% after the FDA granted orphan drug designation for CardiolRx in the treatment for pericarditis. Read more here.

Cardiol Therapeutics receives Nasdaq compliance (NASDAQ:CRDL)

From Seeking Alpha Aug 8, 2023

Cardiol Therapeutics (CRDL) received notice from Nasdaq stating the company has regained compliance with the minimum bid price requirement.The company is now in compliance with...

Cardiol Therapeutics (CRDL) Receives a Rating Update from a Top Analyst

From TipRanks Nov 20, 2022

In a report released on November 16, Charles Duncan from Cantor Fitzgerald reiterated a Buy rating on Cardiol Therapeutics (CRDL – Research Report), with a pr...

Canaccord Genuity Sticks to Their Buy Rating for Cardiol Therapeutics (CRDL)

From TipRanks Nov 20, 2022

In a report released on November 17, Edward Nash from Canaccord Genuity maintained a Buy rating on Cardiol Therapeutics (CRDL – Research Report), with a price...

76 Biggest Movers From Yesterday

From Benzinga May 19, 2022

Gainers Bright Green Corp. (NASDAQ: BGXX) jumped 90.5% to close at $48.08 on Wednesday. Bright Green Corporation, went public on the NASDAQ Tuesday, becoming the first U.S. plant-touching company to list on a major U.S. stock exchange.

FDA Clears Cardiol Therapeutics' IND for CardiolRx in Recurrent Pericarditis

From Benzinga May 17, 2022

The U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) from Cardiol Therapeutics Inc. (NASDAQ: CRDL) to start a Phase 2 open-label pilot study designed to evaluate the tolerance and safety of CardiolRx, in patients with recurrent pericarditis.

ADVERTISEMENT